Clinical Trial Update: Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease [Phase 1]

View source ↗

Summary

Phase 1 trial of MEDI-507 for CD2-positive lymphoproliferative disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoproliferative Disorders

Drugs mentioned

• MEDI-507

Snippet

Sponsor: MedImmune LLC | Conditions: Lymphoproliferative Disorders | Phase 1 | Status: TERMINATED